Bioventus completes divestiture of Advanced Rehab business to Accelmed for $25M cash plus $20M earn-out

Bioventus Inc.

Closed sale of Advanced Rehabilitation business to Accelmed Partners on Dec 31, 2024.
Received $25M cash at closing, subject to working capital adjustments.
Up to $20M in earn-out payments based on 2025-2026 revenue and EBITDA thresholds.
Net closing proceeds of approx $20M to enhance liquidity; company to focus on core businesses.
Accelmed is a private equity firm focused on commercial-stage HealthTech companies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.